Neurological diseases such as Alzheimer's, Parkinson's, and multiple sclerosis are serious health threats worldwide. It is evident that there is a great need for the development of new medications that can block NMDA receptors and, in turn, be used to treat various neurological conditions. According to a recent study published in The Journal of Nuclear Medicine, researchers have developed a new imaging agent that helps treat various neurological diseases.
11C-Me-NB1 is a new positron emission tomography (PET) radioligand that targets GluN1/GluN2B-containing N-methyl-D-aspartate (NMDA) receptors in nerve cells. It inhibits the activation of NMDA receptors, further preventing the fatal Ca2+ levels responsible for cell death. Moreover, the findings further suggest that the availability of such a PET radioligand can help design the appropriate dose of the drugs and minimize the side…
